
Pharma giant GSK agrees $2bn deal to acquire potential liver disease treatment
The drugmaking giant plans to pay $1.2billion upfront to acquire Efirmosfermin By HARRY WISE Updated: 04:39 EDT, 14 May 2025 GSK has struck an agreement worth up to $2billion to buy a medicine that could treat fatty liver disease. The drugs giant plans to …